Pyxis Oncology stock: CEO sets November healthcare conference talks
Published on 11/05/2026 at 03:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUpcoming events sharpen focus
- Tom Civik is scheduled to speak at the Guggenheim Healthcare Innovation Conference and the Stifel Healthcare Conference.
- Pyxis Oncology is advancing MICVO, an antibody-drug conjugate in clinical studies for difficult-to-treat cancers.
- The company is due to present Phase 1 MICVO monotherapy data at the EORTC-NCI-AACR symposium in Barcelona.
Pyxis Oncology said on October 28, 2026, that CEO and Chairman Tom Civik will take part in fireside chats at two upcoming healthcare conferences. The company announced the appearances ahead of the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 9 and the Stifel 2026 Healthcare Conference in New York on November 10.
According to the Pyxis Oncology news release, Civik is scheduled to speak at the Guggenheim event at 9:00 a.m. Eastern Time and at the Stifel conference at 4:40 p.m. Eastern Time. Webcasts and replays are expected to be available through the company's investor relations website.
MICVO remains the central catalyst
The appearances put management communication ahead of further clinical milestones for micvotabart pelidotin, or MICVO. Pyxis is evaluating the antibody-drug conjugate as monotherapy in a Phase 1 study in recurrent and metastatic head and neck squamous cell carcinoma and in combination with Merck's KEYTRUDA in a Phase 1/2 study involving recurrent and metastatic head and neck cancer and other solid tumors.
Pyxis has also scheduled a late-breaking oral presentation of Phase 1 MICVO monotherapy data at the EORTC-NCI-AACR Symposium in Barcelona from November 18 through November 20. The planned presentation concerns previously treated recurrent or metastatic head and neck squamous cell carcinoma; the October announcement provided presentation details rather than clinical results.
Focused clinical-stage biotech
Pyxis Oncology is a Boston-based clinical-stage biopharmaceutical company developing biologics for difficult-to-treat cancers. Its focus is on antibody-drug conjugates and immunotherapies designed to target tumor cells and address immune suppression. The company remains a focused specialist at the clinical-development stage, rather than a diversified commercial pharmaceutical group, with MICVO as its lead program.
Pyxis Oncology at a glance
- Company: Pyxis Oncology, Inc.
- ISIN: US7473241013
- Ticker: PYXS
- Headquarters: Boston, Massachusetts, United States
- Lead program: Micvotabart pelidotin (MICVO)
US biotechnology shares remain sensitive to clinical data, financing conditions and upcoming investor presentations; see the latest S&P 500 market reports.
